HRTXHeron Therapeutics, Inc.

$162M

Q3 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$33M+4.4% YoY

Gross Profit

$23M71.2% margin

Operating Income

-$4M-13.6% margin

Net Income

-$5M-14.8% margin

EPS (Diluted)

$-0.03

QoQ Revenue Growth

-8.9%

Cash Flow

Operating Cash Flow

$3M

Free Cash Flow

$3M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$221M

Total Liabilities

$261M

Stockholders' Equity

-$40M

Cash & Equivalents

$26M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$33M	$31M	+4.4%
Gross Profit	$23M	$13M	+76.6%
Operating Income	-$4M	-$25M	+82.1%
Net Income	-$5M	-$25M	+80.6%

Revenue Segments

C I N V A N T I

$23M72%

Z Y N R E L E F

$6M20%

S U S T O L

$3M9%

HRTX Q3 2024 Earnings — Heron Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena